QNRX$4.02-0.08%
Quoin Pharmaceuticals Ltd.
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$19.3M
Float & O/S:4.47M / 4.8M
Inst Own:30.6%
DilutionScan read 40 of Quoin Pharmaceuticals Ltd.'s SEC filings and found 14 warrant series, 1 convertible, 1 equity line, 3 shelf registrations, 1 S-1 registration and 3 completed offerings on file for QNRX. The latest dilution event on file is a registration statement on Oct 28, 2026. Analysis updated Oct 29, 2026.
Signal8 Summary
QNRX
Pre-revenue biotech, cash extended by new raise
Snapshot
Quoin is a pre-revenue biotech developing rare-disease skin treatments, with $0 in sales and a $15.8M net loss in FY 2025.
What's Happening Right Now
- : On Aug 28, 2026, Quoin reported positive interim Phase 2/3 data for QRX003 in Netherton Syndrome, with 4 of 6 patients hitting the primary endpoint at statistical significance and no treatment-related serious side effects.
- : On Aug 28, 2026, Quoin priced a private placement of up to $50M (about $30.8M upfront), which it says extends its cash runway into the second half of 2029.
- : On Aug 14, 2026, Quoin disclosed FDA conditional approval of the brand name QYLEKI for QRX003, a new patent allowance for a Netherton Syndrome combination treatment, and clearance to start a Phase 2/3 study in Peeling Skin Syndrome.
- : On Jul 9, 2026, the FDA cleared Quoin's IND to begin a Phase 2 study of QRX003 in Peeling Skin Syndrome, expected to start in the second half of 2026.
- : On Jun 18, 2026, Quoin completed a Japanese subsidiary to support planned direct commercialization of QRX003 there, following Japan's orphan drug designation for the product.
